Extracorporeal Stromal Cell Therapy for Subjects With Dialysis-Dependent Acute Kidney Injury

Brian L.K. Miller, Payal Garg, Ben Bronstein, Elizabeth LaPointe, Herb Lin, David M. Charytan, Arno W. Tilles, Biju Parekkadan

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Introduction: The pathophysiology of acute kidney injury (AKI) involves damage to renal epithelial cells, podocytes, and vascular beds that manifests into a deranged, self-perpetuating immune response and peripheral organ dysfunction. Such an injury pattern requires a multifaceted therapeutic to alter the wound healing response systemically. Mesenchymal stromal cells (MSCs) are a unique source of secreted factors that can modulate an inflammatory response to acute organ injury and enhance the repair of injured tissue at the parenchymal and endothelial levels. This phase Ib/IIa clinical trial evaluates SBI-101, a combination product that administers MSCs extracorporeally to overcome pharmacokinetic barriers of MSC transplantation. SBI-101 contains allogeneic human MSCs inoculated into a hollow-fiber hemofilter for the treatment of patients with severe AKI who are receiving continuous renal replacement therapy (CRRT). SBI-101 therapy is designed to reprogram the molecular and cellular components of blood in patients with severe organ injury. Methods: This study is a prospective, multicenter, randomized, double-blind, sham-controlled, study of subjects with a clinical diagnosis of AKI who are receiving CRRT. Up to 32 subjects may be enrolled to provide 24 evaluable subjects (as a per protocol population). Subjects will receive CRRT in tandem with a sham control (0 MSCs), or the low- (250 × 106 MSCs) or high-dose (750 × 106 MSCs) SBI-101 therapeutic. Results: The study will measure dose-dependent safety, renal efficacy, and exploratory biomarkers to characterize the pharmacokinetics and pharmacodynamics of SBI-101 in treated subjects. Conclusion: This first-in-human clinical trial will evaluate the safety and tolerability of SBI-101 in patients with AKI who require CRRT.

Original languageEnglish (US)
Pages (from-to)1119-1127
Number of pages9
JournalKidney International Reports
Issue number5
StatePublished - Sep 2018

All Science Journal Classification (ASJC) codes

  • Nephrology


  • bioreactor
  • critical care
  • ex vivo
  • mesenchymal stem cell


Dive into the research topics of 'Extracorporeal Stromal Cell Therapy for Subjects With Dialysis-Dependent Acute Kidney Injury'. Together they form a unique fingerprint.

Cite this